SCHEMBL24850309

SCHEMBL24850309

O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cc(Cl)[nH]c(=O)c1

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 15/20 0.52
▸ ALDH1A1 P00352 1/20 0.47
▸ TRPV1 Q8NER1 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23091816 0.80 ABL1 (0.58) ABL1
SCHEMBL24850394 0.80 ABL1 (0.47) ABL1TRPV1
SCHEMBL24850252 0.78 ABL1 (0.53) ABL1ALDH1A1TRPV1
SCHEMBL23091809 0.76 ABL1 (0.52) ABL1
SCHEMBL29832702 0.76 ABL1 (0.62) ABL1ALDH1A1TRPV1
SCHEMBL28833677 0.75 TRPV1 (0.61) ABL1ALDH1A1TRPV1
SCHEMBL24849958 0.74 ABL1 (0.52) ABL1ALDH1A1TRPV1
SCHEMBL24850836 0.74 ABL1 (0.52) ABL1ALDH1A1
SCHEMBL24849953 0.73 ABL1 (0.51) ABL1
SCHEMBL30159339 0.73 ABL1 (0.51) ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002346-A1 NEW COMPOUNDS AND METHODS BenevolentAl Bio Limited (GB) 2023-01-05 — — US disclosed
US-20230002346-A1 NEW COMPOUNDS AND METHODS BenevolentAl Bio Limited (GB) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002346-A1 NEW COMPOUNDS AND METHODS ABL2, ABL1, ALK ABL1 2/4885ALDH1A1 651/4885TRPV1 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback